Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic and Geron Extend Oligo Manufacturing Licensing Agreement

NEW YORK, June 4 - Transgenomic and Geron announced today an expanded non-exclusive licensing agreement covering the manufacture of oligonucleotides.

 

Transgenomic of Omaha, Neb., extends a license to manufacture phosphoramidate-based oligos based on the patented processes acquired by Menlo Park, Calif.-based Geron from Lynx Therapeutics in 2002. The company will pay undisclosed royalties on the sales of diagnostic and therapeutic products, as well as on those products for research use.

 

Phosphoramidate-based oligos are synthetic nucleic acids.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.